GSK, Moderna and mRNA
GSK sues Moderna for US patent infringement over COVID, RSV vaccines
British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing its American rival of violating GSK's patent rights in messenger RNA (mRNA) technology with its blockbuster COVID-19 vaccine Spikevax.
GSK takes mRNA patent fight to Moderna, suing over vaccines for COVID and RSV
Nearly six months after lodging a similar complaint against Pfizer and BioNTech over the partners’ COVID shot Comirnaty, GSK is targeting Moderna in a pair of lawsuits alleging the Massachusetts-ba | GSK is targeting Moderna in a pair of lawsuits claiming the mRNA specialist violated multiple patents with its vaccines Spikevax and mRESVIA.
GSK sues Moderna over mRNA vaccine technology
GlaxoSmithKline is suing Moderna for allegedly using technology patented by GSK in its COVID-19 vaccine. Why it matters: It's the latest in a series of legal fights over who owns the intellectual property behind mRNA technology and whether some companies are entitled to royalties on future sales.
Moderna's Covid, RSV Vaccines Targeted in Two GSK Patent Suits
Moderna Inc.’s shots for Covid-19 and respiratory syncytial virus infringe as many as seven GSK Plc patents related to mRNA vaccine-delivery technology, the company said in a pair of federal lawsuits.
GSK Sues Moderna for Alleged Patent Infringement on COVID-19, RSV Vaccines
The lawsuits claim that Moderna used and profited from crucial mRNA technology in its COVID-19 vaccine Spikevax and respiratory syncytial virus shot mResvia.
GSK sues Moderna over Covid and RSV vaccines
GSK filed two lawsuits at the US District of Delaware on 15 October saying that Moderna’s mRNA vaccine product Spikevax infringed up to seven patents covering lipid mRNA vaccine formulation technology. It is also suing Moderna for infringing the same mRNA technology through the sale of its recently approved RSV shot mResvia.
Northwestern sues Moderna for patent infringement over COVID-19 vaccines
Moderna was hit with a new patent lawsuit on Wednesday in Delaware federal court from Northwestern University, which accused the company of misusing the school's innovations to develop its blockbuster COVID-19 vaccine Spikevax.
Northwestern sues Moderna for alleged patent infringement in COVID shots
Moderna is facing allegations that it misused innovations from researchers at Northwestern University to develop its mRNA COVID-19 vaccines, which became widely available to the public in 2021 to combat the pandemic.
British drugmaker sues Moderna for patent infringement related to mRNA vaccines
A British drugmaker, GlaxoSmithKline (GSK), has sued American pharmaceutical company Moderna claiming it violated patent rights in its mRNA technology used to develop its COVID-19 and RSV vaccines.
GSK claims Moderna infringed mRNA vaccine patents
The pharma’s lawsuit focuses on scientific work that helped clear the path for creating mRNA vaccines to fight the COVID-19 pandemic.
GSK, Pfizer RSV vaccine sales fall in US as millions fewer people line up
U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...
WebMD10h
RSV Vaccine Shows Strong Protection for Older Adults
A large new study says the RSV vaccine is 80% effective at preventing hospitalization in older adults due to complications from the illness, and works just as well at protecting them from death or ...
MyChesCo on MSN4d
GSK’s AREXVY Vaccine Shows Promising Results Across Three RSV Seasons
GSK plc (LSE/NYSE: GSK) has released new data from the AReSVi-006 Phase III trial, demonstrating the efficacy and safety of ...
pharmaphorum3d
GSK turns its guns on Moderna in mRNA jab patent dispute
GSK has filed a pair of lawsuits against Moderna, claiming infringement of patents covering mRNA vaccines for COVID-19 and respiratory syncytial virus (RSV). According to court documents ...
GSK, Pfizer Face Declining Respiratory Syncytial Virus Vaccine Sales Due To Narrow Age Recommendations
RSV vaccine sales from GSK and Pfizer have dropped significantly following revised CDC guidelines, narrowing the eligible age ...
GSK Arexvy protects from RSV over three full seasons
GSK (GSK) announces that its Arexvy vaccine shows promise in protecting adults aged 60+ against RSV over three seasons in a ...